drugset / Trial / NCT00269906

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty

NCT00269906

Phase 3 Completed 1265 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of abciximab, an anti-platelet therapy, versus placebo in patients with unstable angina who are not responding to standard medical therapy and who are eligible for coronary angioplasty.

Timeline

Start
1993-05
Primary completion
1995-12
Completion
1995-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Abciximab Monoclonal antibody 10 ug Intravenous